Celltrion's Steqeyma Tops 16% U.S. Market Share
In the US ustekinumab market, Celltrion’s autoimmune disease treatment ‘Steqeyma’ exceeded a 16% market share in about a year since its launch.According to the pharmaceutical market research firm IQVIA, Steqeyma recorded a 16.2% market share in the US market in July. This is a figure that has increa
In the US market for the autoimmune disease treatment ustekinumab, Celltrion's product Steqeyma has achieved a record 16% market share, according to IQVIA's latest figures. This market share figure has grown by 6% over the course of five months, rising from a 10.2% share in February to 16.2% in July. The success can be attributed to Celltrion's US subsidiary, which employs a localized sales strategy.
Within a year of its launch, Steqeyma gained reimbursement coverage as a preferred drug on insurance formularies of major pharmacy benefit managers (PBMs) in the US. The strategy helped the product build its strong market position. The blood cancer treatment Truxima, a biosimilar, leads the market with a 38.6% market share, recording six consecutive months of top prescription ranking.
Inflectra, a leading product in the infliximab market, maintains a 30.7% market share. Celltrion aims to boost sales by introducing follow-up products with high-profit margins, such as the chronic spontaneous urticaria treatment Omlyclo.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
